Explore

Trendline Trendline
FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability
Trendline Trendline
FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time
Trendline Trendline
Experts Warn Against Risks of Consuming Bagged Lettuce

Experts Warn Against Risks of Consuming Bagged Lettuce

Experts Warn Against Risks of Consuming Bagged Lettuce
Trendline Trendline
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence

FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence

FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence
Trendline Trendline
NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy

NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy

NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy
Rapid Read Rapid Read
Treasury Secretary Bessent Highlights Impact of Trump's Tax Policies on 30 Million Americans

Treasury Secretary Bessent Highlights Impact of Trump's Tax Policies on 30 Million Americans

Treasury Secretary Scott Bessent announced that nearly 30 million Americans have benefited from President Trump's tax policies, specifically the 'No Tax on Tips' and 'No Tax on Overtime' deductions. These measures are part of the One Big Beautiful Bill Act (OBBBA), which also includes tax cuts on vehicle loan interest and increased deductions for state and local taxes. Bessent, alongside Rep. Mike Lawler, discussed these policies with small business owners in the Hudson Valley, emphasizing their positive impact on the workforce. The policies have reportedly encouraged more individuals to enter the workforce, as seen in the hospitality sector where businesses are experiencing an influx of job applicants.
Trendline Trendline
ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals

ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals

ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals
Trendline Trendline
Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products

Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products

Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products
AP News AP News
Toxic Mud? Hawaii's North Shore Flooding Likely Diluted Pesticide Risk

Toxic Mud? Hawaii's North Shore Flooding Likely Diluted Pesticide Risk

Residents on Hawaii's North Shore are dealing with mud and debris after severe flooding and have expressed concerns about potential exposure to toxic farm chemicals from upstream agricultural operations
Rapid Read Rapid Read
Consumer Reports Warns FDA Policy Change Could Mislead on Food Labels

Consumer Reports Warns FDA Policy Change Could Mislead on Food Labels

Consumer Reports has raised concerns about a new FDA policy that could make food labels like 'no artificial colors' misleading. The policy redefines what constitutes an artificial color, now only excluding FD&C dyes and petroleum-based dyes like Red 40, Yellow 5, and Blue 2. Other synthetic additives, such as titanium dioxide, which is banned in the EU for toxicity concerns, may still be present in products labeled as having no artificial colors. This change could lead to consumer confusion and necessitates more careful scrutiny of ingredient lists by shoppers.
Trendline Trendline
Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment

Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment

Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment
Trendline Trendline
Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology